PF-07836391

PF-07836391 is a self-amplifying RNA (saRNA) vaccine developed by Pfizer for the prevention of human influenza. It is designed as a prophylactic vaccine and utilizes saRNA technology to induce an immune response against influenza virus infection. The drug is administered via intramuscular injection and has completed Phase 1 clinical trials in healthy individuals to evaluate its safety, tolerability, and immunogenicity[1][3][4]. The primary indication under investigation is influenza (human), with development focused on infectious and respiratory diseases[1][3]. The drug leverages saRNA technology, which allows for amplification of the antigen-coding sequence within host cells, potentially enabling lower dosing compared to conventional mRNA vaccines. Development status as of early 2025 remains at Phase 1 for human influenza prevention[1][3][4].

Other names

self-amplifying RNA vaccine Pfizerself-amplifying ribonucleic acid vaccine